News
URGN
13.79
-2.96%
-0.42
Weekly Report: what happened at URGN last week (0415-0419)?
Weekly Report · 3d ago
Pharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains?
NASDAQ · 3d ago
UroGen Pharma Price Target Maintained With a $54.00/Share by HC Wainwright & Co.
Dow Jones · 04/18 10:33
HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $54 Price Target
Benzinga · 04/18 10:23
Buy Rating Affirmed for Urogen Pharma Amid Promising Clinical Data and Strategic Conference Presentations
TipRanks · 04/18 10:15
UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
New data on investigational drug UGN-102 (mitomycin) and JELMYTO will be presented at the American Urological Association (AUA) 2024 Annual Meeting in San Antonio, Texas. UroGen anticipates completing its new drug application for ugn-102 in September 2024. The drug is in Phase 3 development for the treatment of LG-IR-NMIBC.
Barchart · 04/17 11:02
UroGen Announces FDA Acceptance Of IND Application For UGN-103, A Next Generation Mitomycin-Based Formulation For Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
UroGen plans to initiate a Phase 3 study to explore the safety and efficacy of UGN-103 in 2024. Anticipated advantages include a new 80 mg mitomycin dosage strength for low-grade intermediate-risk non-muscle invasive bladder cancer. The FDA accepted the Company's Investigational New Drug application for Ugn-103. UroGen is a biotech company dedicated to developing and commercializing novel cancer treatments.
Benzinga · 04/15 12:11
UROGEN PHARMA LTD - FOR UGN-102 POTENTIAL FDA DECISION AS EARLY AS Q1 OF 2025 IF PRIORITY REVIEW IS GRANTED BY FDA
Reuters · 04/15 12:00
Weekly Report: what happened at URGN last week (0408-0412)?
Weekly Report · 04/15 10:54
Two Buys; Two Holds, by Oppenheimer
Two Buys; Two Holds, by Oppenheimer analysts provided updates on five stocks -- two buys and two holds. All five of these companies are rated outperform. Cloudflare Inc. Class A has corrected into its $91 support. CarMax, SEIC, TRU, NET, URGN are among the five companies.
Seeking Alpha · 04/09 13:35
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Omeros (OMER) and Urogen Pharma (URGN)
TipRanks · 04/09 11:40
Weekly Report: what happened at URGN last week (0401-0405)?
Weekly Report · 04/08 10:59
Urogen Pharma’s Strategic Defense and Pipeline Progress Bolster Buy Rating
TipRanks · 04/04 10:25
Urogen files patent suit against Teva over cancer therapy
Healthcare Urogen files patent suit against Teva over cancer therapy. Jelmyto has added $82.7M in sales for UroGen in 2023. Israeli drugmaker sought U.S. Approval to market a generic version of the drug for bladder cancer.
Seeking Alpha · 04/03 12:28
UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals Alleging Infringement Of US Patent Numbers 9,040,074 And 9,950,069
UroGen Pharma Ltd. Alleges infringement of U.S. Patent Numbers 9,040,074 and 9,950,069 for JELMYTO. Both patents are listed in the FDA's approved drug list for urothelial and specialty cancers.
Benzinga · 04/03 12:26
UroGen Pharma Files Patent Infringement Lawsuit Against Teva Pharma
NASDAQ · 04/03 12:25
Weekly Report: what happened at URGN last week (0325-0329)?
Weekly Report · 04/01 10:57
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Landos Biopharma, Inc. Shares jumped 171.2% to $21.70 on Monday. AbbVie and Landos signed a definitive agreement to acquire the company. Altamira Therapeutics Ltd. Shares climbed 70.1% after falling around 22% on Friday. GameStop Corp. Shares rose 8.4% after the company announced a separation.
Benzinga · 03/25 18:44
More
Webull provides a variety of real-time URGN stock news. You can receive the latest news about Urogen Pharma through multiple platforms. This information may help you make smarter investment decisions.
About URGN
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).